Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049778 | 0.83 | EPHX2 (0.40) | EPHX2RAB9AESRRGNPC1NR1H4 | |
| SCHEMBL6563136 | 0.80 | P2RX7 (0.41) | RAB9AMAPTESRRGNPC1 | |
| SCHEMBL4889952 | 0.79 | TRPV1 (0.49) | — | |
| SCHEMBL4888259 | 0.77 | ALDH1A1 (0.53) | EPHX2RAB9AESRRGNPC1LMNA | |
| SCHEMBL12049762 | 0.77 | TAAR1 (0.41) | EPHX2RAB9AESRRGNPC1LMNA | |
| SCHEMBL12049763 | 0.77 | TRPV1 (0.42) | EPHX2ESRRGNR1H4 | |
| SCHEMBL12049764 | 0.73 | MEN1 (0.44) | EPHX2RAB9ALMNANR1H4HDAC3 | |
| SCHEMBL4880046 | 0.73 | LMNA (0.53) | MAPTLMNAALDH1A1 | |
| SCHEMBL20625626 | 0.71 | LMNA (0.50) | EPHX2RAB9AMAPTLMNANR1H4 | |
| SCHEMBL4892411 | 0.70 | TRPV1 (0.66) | EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| EP-1303483-A4 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | EPHX2 3810/4885RAB9A 997/4885MAPT 1674/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | EPHX2 3840/4885RAB9A 778/4885MAPT 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.